Preclinical Safety Evaluation of mRNA Cancer Therapeutics: A Platform Approach

Time: 2:30 pm
day: Day One


  • Toxicology assessment of RNA-therapeutics can be split into two parts – assessment of RNA-LNP characteristics and the assessment of translated protein
  • Toxicity data of an RNA-LNP platform facilitating various RNA payloads show a comparable safety profile in non-clinical safety studies
  • Platform-based strategy could reduce the need for toxicity tests involving animal testing (3R)